Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.

Item

http://www.wikidata.org/entity/Q33416122

Q33416122

about

Molecular-targeted first-line therapy for advanced gastric cancer New advances in targeted gastric cancer treatment Current and emerging therapies in unresectable and recurrent gastric cancer Recent updates of precision therapy for gastric cancer: Towards optimal tailored management Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?Biomarker development in MET-targeted therapy Perioperative and Palliative Chemotherapy for Esophageal Cancer Advanced gastric cancer: Current treatment landscape and future perspectives Novel targets in the treatment of advanced gastric cancer: a perspective review Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application Targeted therapy for advanced gastric cancer: A review of current status and future prospects Changing strategies for target therapy in gastric cancer Personalized medicine in gastric cancer: Where are we and where are we going?c-Met as a Target for Personalized Therapy Clinical significance of MET in gastric cancer Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological features Second-line treatment of metastatic gastric cancer: Current options and future directions State of the art management of metastatic gastroesophageal cancer Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives Companion diagnostics for the targeted therapy of gastric cancer Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy Advances in targeted therapies and new promising targets in esophageal cancer Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity Gastric Cancer: New Drugs - New Strategies Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers Molecular targeted therapy for the treatment of gastric cancer Gastric cancer: current and evolving treatment landscape From molecular classification to targeted therapeutics: the changing face of systemic therapy in metastatic gastroesophageal cancer Translating genomic profiling to gastrointestinal cancer treatment.Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions?Molecular classifications of gastric cancers: Novel insights and possible future applications.Biologic therapy in esophageal and gastric malignancies: current therapies and future directions Clinical impact of tumour biology in the management of gastroesophageal cancer Current status of novel agents in advanced gastroesophageal adenocarcinoma.Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression.Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression Patient-Derived Gastric Carcinoma Xenograft Mouse Models Faithfully Represent Human Tumor Molecular Diversity.Prognostic value of MET protein overexpression and gene amplification in locoregionally advanced nasopharyngeal carcinoma.A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?Targeted therapy in gastroesophageal cancers: past, present and future.

P2860

Q26471049-46E30763-2138-476E-BEDE-388377A1B361 Q26738548-682EAE93-34A6-4896-82E9-EF067ACB41C1 Q26745453-191D49CB-BAA8-44E0-A520-ABDE53FA87AF Q26746246-4E550959-4430-4FB8-9ABF-4249BF2029E9 Q26748581-628F02A9-47FE-4069-9AD9-D8B7062E8F31 Q26751332-AB22C5C3-60DA-4704-9EC8-A0C5BB8A19F6 Q26753865-5B0C6A47-8B54-464C-97BF-5F9EC062E6A4 Q26764934-A4706E70-702F-417A-A5FD-5DFE237D4188 Q26765208-C75E8CA4-4E9B-42E5-B9C8-FD9ED92D9786 Q26765941-F79F700B-0EA4-43B4-AA0D-3D704E0CC457 Q26774138-9D29CDF6-7185-4B37-AA3B-1257EC582E36 Q26774513-CA483642-7767-4E19-89AE-2FADFD083C50 Q26774521-4DC1762D-DA74-493D-8FA1-2B25B895AFCE Q26775483-3892757C-12B4-40DD-B942-48D9D7D582EA Q26776190-E4AC943A-3B99-44A5-95EF-BC54400ADD57 Q26776198-A294A820-B4ED-4C30-9BA0-63EA238D1438 Q26778027-A8969AB8-1EA1-44AB-81AB-2B7CD6D82173 Q26779217-FFC90945-84BC-4E08-BCB8-E937304A2982 Q26779725-926782DC-4B63-4D08-BCAE-DCEC9E43A229 Q26780298-902C905D-9921-4C9A-981D-99ABC3C9CFA6 Q26798420-294BFC07-8F8E-43DD-8046-80B7DD239C02 Q26825957-A826AA9E-FAFD-4370-AA13-24A14045F9EF Q26992272-48EACE77-68ED-436D-9B73-645E74664DBD Q27028079-00C86E1F-20A3-41DC-A4AE-385FDCB3BEA2 Q28066550-886426D5-8947-4FBD-A381-A8FCE66382F9 Q28072433-7A2A04DF-52AB-43B6-A5C8-039086717403 Q28073757-E2E2425E-5D65-483E-8A2B-E1693FB969F9 Q28082921-EAD9C30B-3B86-42F3-8B3E-7D4DCB66DB24 Q30239109-634D0676-198E-410B-B9FE-E1D5B54E6692 Q31012680-EE90E2E9-60FA-479A-8B1C-37AC9E8D2597 Q33696201-34B3A867-62CF-4116-9BA7-4BA9DFC417F1 Q33895597-C519AAC9-7D19-416F-A5C6-90B31C47EEAD Q33922534-CD9FAECE-EA5F-4347-8EF0-85FDFDCE8E7A Q34962039-6D26831C-C7C6-46DE-A439-92F73FB2EBE9 Q35201636-2AD67AC2-C7FD-479D-8229-4253187AC95D Q35677873-41F04AF3-73B4-4232-A38E-52D31BA20DA1 Q35719104-EA1E2E2A-3465-43A6-A65D-434C4CC8D035 Q35955290-3F436D11-E8AC-4675-B65E-A2C4FDCD2471 Q36215991-5A0517CC-A496-4C65-86DB-1AD231022B8E Q36294579-DDAB04B2-769C-4FB9-B064-BFADF2C95042

P2860

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.

Item

http://www.wikidata.org/entity/Q33416122

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu